863 results about "Doderlein's bacillus" patented technology

The invention discloses lactobacillus kefiranofaciens IMAU12319 and application thereof, belongs to the technical field of microorganisms, and particularly relates to lactobacillus kefiranofaciens IMAU12319 which is preserved in China General Microbiological Culture Collection Center (CGMCC) on July 8, 2024, the preservation address is No. 3, No.1 yard, West Beichen Road, Chaoyang District, Beijing, and the number is CGMCC No.31224. The lactobacillus kefiranofaciens IMAU12319 has the advantages that the lactobacillus kefiranofaciens IMAU12319 can be used for preparing the lactobacillus kefiranofaciens IMAU12319, and the lactobacillus kefiranofaciens IMAU12319 can be used for preparing the lactobacillus kefiranofaciens IMAU12319; the invention also relates to an application of the lactobacillus kefiranofaciens IMAU12319 in preparation of a probiotic agent capable of resisting gastrointestinal digestion. The strain disclosed by the invention not only shows good gastrointestinal tract endurance capacity, but also shows relatively strong potential in the aspects of intestinal adhesion, oxidation resistance and bacteriostasis, and has a wide application prospect in leavening agent strains.

The invention discloses a plant lactobacillus with a bacteriostatic effect and application of the plant lactobacillus. The lactobacillus plantarum is named as lactobacillus plantarum C07, the preservation number is CCTCC NO: M20242086, the preservation unit is China Center for Type Culture Collection, the preservation time is September 26, 2024, and the preservation address is Wuhan University, Wuhan University, No. 299, eight road, Wuchang District, Wuhan City, Hubei Province. The strain can produce lactic acid and indole-3-lactic acid at high yield, has a very strong antibacterial effect on multiple putrefying and pathogenic microorganisms such as staphylococcus aureus, escherichia coli, listeria monocytogenes, pseudomonas aeruginosa, salmonella and mould, and is a broad-spectrum antibacterial microorganism.

The invention provides lactobacillus crispatus, which is preserved in the general microbiological center of the China Committee for Culture Collection of Microorganisms on February 7, 2023, and the preservation number is CGMCC (China General Microbiological Culture Collection Center) No. 26503. The bacillus subtilis can play a relatively strong role in inhibiting pathogenic bacteria such as gardnerella vaginalis, escherichia coli and staphylococcus aureus at the same time, and also has a certain role in inhibiting candida albicans, two-way proteurella and Atortoria vaginalis. Therefore, the lactobacillus crispatus has the potential of maintaining the environment in the vagina to be faintly acid and improving the mucosal immunity and infection resistance of a host, and can be used for preventing and treating vaginal infection and inflammation, and maintaining, improving or recovering the steady state of the environment in the vagina.

The invention relates to the technical field of microorganisms, and provides lactobacillus mucilaginosus for maintaining genital tract health and preventing genital tract infection and application of lactobacillus mucilaginosus. Fermented mucus lactobacillus for maintaining genital tract health and preventing genital tract infection is named as FMTA1113H and is preserved in China General Microbiological Culture Collection Center (CGMCC) on April 22, 2025, the preservation address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing, and the preservation number is CGMCC NO.34291. The invention further discloses a preparation method of the fermented mucus lactobacillus for maintaining genital tract health and preventing genital tract infection. According to the technical scheme, the problems that female genital tracts are prone to infection and relapse is prone to occurring after infection in the prior art are solved.

A breast milk-derived Limosilactobacillus fermentum MSJK0025 capable of improving the intestinal flora condition and the use thereof. The breast milk-derived Limosilactobacillus fermentum MSJK0025 is deposited in the China General Microbiological Culture Collection Center with a deposit number of CGMCC No. 26426. The breast milk-derived Limosilactobacillus fermentum is a new strain isolated from breast milk of healthy puerperae, and is referred to as Limosilactobacillus fermentum MSJK0025. The strain has a good antibiotic sensitivity and stable inheritance of traits, has a good tolerance to acid, bile salts and artificial gastric / intestinal fluid, and has a fast growth rate and good safety. Furthermore, the strain has a strong intestinal colonization capability and can effectively inhibit intestinal pathogenic bacteria such as Escherichia coli, Staphylococcus aureus, Salmonella typhimurium and Candida albicans, but has no inhibitory effects on intestinal probiotics such as Lactobacillus and Bifidobacterium.

The invention discloses a microbial compound feed additive, which is prepared from the following ingredients in parts by weight: 35 to 45 parts of traditional Chinese medicine residues, 25 to 35 parts of soybean meal, 15 to 25 parts of bran, 8 to 12 parts of corn flour, 0.3 to 0.7 part of selenium-enriched yeast, 8 to 12 parts of aspergillus niger spore powder, 10 to 15 parts of bacillus subtilis, 6 to 9 parts of lactobacillus plantarum and 5 to 8 parts of candida utilis. The invention relates to the technical field of feed additives, through the synergistic effect of the aspergillus niger, the bacillus subtilis, the lactobacillus plantarum and the candida utilis, the aspergillus niger can generate various enzymes, and decomposition of raw materials and release of nutritional ingredients are facilitated; the bacillus subtilis can enhance the immunity of livestock and poultry and inhibit the growth of harmful bacteria; lactobacillus plantarum can regulate intestinal microecological balance and promote digestion and absorption; candida utilis is rich in protein and vitamins and provides nutrition for livestock and poultry, the four components cooperate with each other, the function limitation of a single strain is broken through, and the health level and production performance of livestock and poultry are comprehensively improved.

The preservation number of the bacterial strain is CGMCC (China General Microbiological Culture Collection Center) NO.33629, the preservation date of the bacterial strain is February 24, 2025, the preservation classification of the bacterial strain is Lactobacillus sakei, and the preservation unit of the bacterial strain is China General Microbiological Culture Collection Center. The strain provided by the invention can reduce the concentration of blood uric acid, relieve kidney inflammation caused by hyperuricemia, improve the protein level of a kidney uric acid excretion channel and reduce the expression level of uric acid resorption protein.

The invention is applicable to the technical field of biology, and provides edible lactobacillus for relieving pulmonary fibrosis and application thereof, the edible lactobacillus for relieving pulmonary fibrosis provided by the embodiment of the invention is named as lactobacillus plantarum ZYHL3, is preserved in China Center for Type Culture Collection (CCTCC), has a preservation number of CCTCC No: M 2025127, has a preservation number of CCTCC No: M 2025127, and has a preservation number of CCTCC No: M 2025127, a preservation number of CCTCC No: M 2025127, a preservation number of CCTCC No: M 2025127, a preservation number of CCTCC No: M 2025127, and a preservation number of CCTCC No: M 2025127. Lung inflammation and pulmonary fibrosis of mice can be remarkably relieved and disease prognosis can be improved by adjusting intestinal flora diversity and metabolic profiles, so that a new thought can be provided for preventing and treating pulmonary fibrosis diseases such as idiopathic pulmonary fibrosis and the like.

The invention relates to the technical field of microorganisms, and provides lactobacillus crispatus FMTA1145 C with a bacteriostatic effect and application of the lactobacillus crispatus FMTA1145 C. The lactobacillus crispatus FMTA1145 C is preserved in the China General Microbiological Culture Collection Center (CGMCC) on April 22, 2025, the address of the lactobacillus crispatus FMTA1145 C is No.3, No.1 yard, Beichen West Road, Chaoyang District, Beijing, and the preservation number of the lactobacillus crispatus FMTA1145 C is CGMCC NO.34293. The lactobacillus crispatus FMTA1145 C has the advantages that the lactobacillus crispatus FMTA1145 C has the antibacterial effect, and the lactobacillus crispatus FMTA1145 C has been preserved in the China General Microbiological Culture Collection Center (CGMCC) on April 22, 2025; according to the technical scheme, the problem that the existing lactobacillus crispatus has a poor treatment effect on female vaginal diseases in the prior art is solved.

The invention relates to the field of biological medicine, and provides a preparation method of a fermentation product containing giant salamander peptide, which comprises the steps of stepped enzymolysis pretreatment, staged inoculated fermentation, synergistic enzymolysis and molecular weight grading purification. The method comprises the following steps: firstly, carrying out staged enzymolysis on giant salamander tissues by utilizing pepsin, trypsin and flavourzyme to obtain a primary peptide solution; then, bacillus subtilis, lactobacillus plantarum and bifidobacterium are adopted for directional fermentation, and flora metabolism is optimized through dissolved oxygen control and pH automatic regulation. Then, compound protease is added for secondary enzymolysis, so that the yield of the small molecule peptide is increased. And finally, carrying out ultrafiltration and nanofiltration graded purification, vacuum concentration, freeze drying and gamma-ray sterilization to obtain the micromolecular giant salamander peptide. The molecular weight of the obtained product is mainly distributed within 0.5-5 kDa (lt), and the proportion of 3 kDa is larger than or equal to 80%), the DPPH free radical scavenging rate is larger than or equal to 85%, the ABTS < + > scavenging rate is larger than or equal to 80%, and the obvious anti-oxidation and auxiliary liver protection effects are achieved.

The invention discloses lactobacillus fermentum with a hypoglycemic function and application of the lactobacillus fermentum. According to the invention, lactobacillus fermentum with high hypoglycemic ability is screened from Yunnan Baoshan freshly brewed yoghurt samples, the strain is preserved in China Center for Type Culture Collection, and the preservation number is CCTCC NO: M 20241504. In the fermentation process of the strain, alpha-glucosidase and alpha-amylase can be inhibited, and the inhibition rates are 43.91% and 59.44% respectively. The bacterial colony morphology of the lactobacillus fermentum E003 is milky white, semitransparent, relatively moist and smooth, the edge is neat, and obvious bulges are formed. When being used for preparing the anti-sugar fermented milk, the fermented milk can also inhibit alpha-glucosidase and alpha-amylase, and meanwhile, the fermented milk also has various characteristic nutritional ingredients; the lactobacillus fermentum E003 fermentation liquor also has relatively strong bacteriostatic ability, antioxidant activity and GABA high-yield ability.

The invention provides a halite-containing probiotic preparation for improving gastrointestinal environment and a preparation method, the halite-containing probiotic preparation comprises the following components in parts by weight: 60-70 parts of a probiotic composition, the probiotic composition comprises lactobacillus casei Zhang, animal bifidobacterium subsp. Lactis V9, lactobacillus plantarum P-01, animal bifidobacterium subsp. Lactis B-01 and casei paracasei LC-11, the weight ratio is 3: 2: 2: 1: 1. 1.2 to 3.5 parts of nanoscale refined halite; 10 to 15 parts of a microcapsule embedding material; 0.6 to 1.2 parts of an antioxidant system; 15 to 30 parts of auxiliary materials; the probiotic preparation disclosed by the invention has the characteristics of obvious strain combination advantage, nano-scale halite protection and synergism, accurate release of a multi-layer microcapsule structure, synergistic effect of an antioxidant system and the like, the survival rate of probiotics, gastrointestinal tract tolerance and intestinal colonization capacity are remarkably improved, and a new technical scheme is provided for improving gastrointestinal health.

The invention relates to the technical field of biology, and provides a probiotic composition for relieving sarcopenia obesity and application of the probiotic composition. The composition comprises at least two of lactobacillus plantarum, lactobacillus rhamnosus and bifidobacterium animalis subsp. Lactis. Wherein the preservation number of the lactobacillus plantarum is CGMCC (China General Microbiological Culture Collection Center) No.25839; the preservation number of the lactobacillus rhamnosus is CGMCC (China General Microbiological Culture Collection Center) No.26968; the preservation number of the animal bifidobacterium subsp. Lactis is CGMCC (China General Microbiological Culture Collection Center) No. 27998. The composition disclosed by the invention can be used for increasing the muscle content of an organism, improving the muscle tissue form, increasing adenosine triphosphate and inhibiting abnormal increase of body weight, so that the composition can be used for effectively preventing and treating sarcopenia obesity.

The invention discloses a bacterium-enzyme synergistic fermentation method for sweet potato residues, which can realize rapid fermentation and has high protein content of the fermented sweet potato residues. According to the method, high-temperature-resistant alpha-amylase, cellulase and pectinase are used for carrying out enzymolysis on the sweet potato residues to decompose the sweet potato residues into reducing sugar, cellulose is preliminarily decomposed, and rapid and accurate starch conversion and cellulose degradation are carried out; a multi-bacterium combination of efficient degradation fibers, candida utilis capable of producing mycoprotein, lactobacillus plantarum JM113, bacillus subtilis and aspergillus niger is used for fermentation, so that the mycoprotein level in the fermented sweet potato residues is further improved, the nutritional value and the in-vitro digestibility are improved, the feeding price of the fermented sweet potato residues is improved, and the cost problem caused by high-moisture treatment is reduced; therefore, the economic value of the sweet potato residues is comprehensively improved, and the method has practical significance in waste utilization of the sweet potato residues, reduction of protein feed cost, alleviation of waste residue environmental pollution and improvement of industrial economic benefits. The method is suitable for popularization and application in the technical field of biological fermentation.

The invention discloses an application of Lactobacillus plantarum in at least one of the following items: a1, an application in improving the silage quality of silage, a2, an application in improving the silage quality, a3, an application in improving the silage quality, a4, an application in improving the silage quality, and a5, an application in improving the silage quality. A2, application in preparation of silage; a3, application in preparation of a silage additive; the strain name of the lactobacillus plantarum is LA2, the lactobacillus plantarum is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number of the lactobacillus plantarum is CGMCC No. 33484. According to the invention, the lactobacillus plantarum or the microbial inoculum thereof or the silage additive thereof is added into the silage for the first time, and tetracycline resistance genes in the silage can be remarkably reduced; after the lactobacillus plantarum or the microbial inoculum thereof or the silage additive thereof disclosed by the invention is added, the generation and residue of tetracycline resistance genes in feed can be reduced, the propagation of the tetracycline resistance genes in a food chain is reduced, the safety of forage grass is ensured, and the damage to animals, environment and human bodies is reduced; and the drug resistance of human pathogenic bacteria is reduced while the health level of animals is improved.

The invention relates to the field of biotechnology and female health care, in particular to a stachyose composition for promoting micro-ecological regulation of lactobacillus and application of the stachyose composition, and the composition comprises stachyose and pharmaceutically acceptable auxiliary materials. The stachyose is used as prebiotics to selectively promote proliferation and colonization of the lactobacillus crispatus, the combination of 1%-5% of the stachyose and 0.1%-0.5% of the lactic acid can promote proliferation of the lactobacillus crispatus, the lactobacillus crispatus is one or more of the lactobacillus crispatus, the lactobacillus plantarum and the lactobacillus acidophilus, and the combination of 1%-5% of the stachyose and 0.1%-0.5% of the lactic acid can inhibit gardnerella and candida albicans. The stachyose composition disclosed by the invention is in the form of slow-release gel and bath foam; the composition can be used for treating or preventing bacterial vaginitis, colpitis mycotica and related symptoms, has the advantages of no antibiotics, no drug resistance, high safety and the like, and is suitable for the fields of vagina local nursing and micro-ecological regulation.

The invention relates to the field of modified milk, in particular to pasteurized modified milk with a lead ion emission reduction function and application of the pasteurized modified milk. The pasteurized modified milk provided by the invention contains lactobacillus mucus fermentation B44, wherein the preservation number of the lactobacillus mucus fermentation B44 is CGMCC (China General Microbiological Culture Collection Center) No.17321. Compared with a control sample and other strains, the lactobacillus mucilaginosus B44 in the pasteurized modified milk provided by the invention can remarkably reduce the lead content in intestinal content supernatant, and results of in-vivo experiments of rats show that the lactobacillus mucilaginosus B44 can remarkably reduce the blood lead concentration, the lead content in livers and the lead content in kidneys of drinking objects, so that the lactobacillus mucilaginosus B44 can be used for preparing the pasteurized modified milk. The discharge of lead in excrement can be increased, and liver oxidative damage caused by lead poisoning can be effectively relieved, so that the method can be applied to research on in-vivo emission reduction of lead.

The invention discloses a novel microecological preparation composition for preventing and treating feline plague and application of the novel microecological preparation composition, and belongs to the technical field of microecological preparations. The recombinant lactobacillus plantarum NC8-VP2 constructed by a genetic engineering means can efficiently express the feline plague VP2 protein, and finally, a protective antigen expressed by the recombinant lactobacillus plantarum efficiently stimulates an organism to generate a specific antibody, so that the feline plague is prevented, and the use of chemical drugs is reduced. Recombinant escherichia coli BL21-pET32a-MLT constructed by the research can secrete and express melittin (MLT), large-scale production of melittin is realized, melittin and recombinant lactobacillus plantarum NC8-VP2 are further taken as active ingredients, a novel microecological preparation composition for preventing and controlling feline plague is developed and prepared, the morbidity of feline plague can be reduced, clinical symptoms of sick animals can be improved, and the novel microecological preparation composition has a good application prospect. Therefore, the compound has a relatively good application prospect in the aspect of preventing and treating feline plague.

The invention belongs to the technical field of microorganisms, and particularly relates to a preservative and bacteriostatic metabiotic composition for food as well as a preparation method and application of the preservative and bacteriostatic metabiotic composition. The raw materials of the postbiotic composition comprise inactivated thalli of compound probiotics and metabolites of the compound probiotics; the compound probiotics comprise lactobacillus casei Zhang, bifidobacterium animalis subsp. Lactis V9, lactobacillus plantarum P-8 and lactobacillus plantarum PB-2. Through mutual cooperation of the four strains, a culture substrate can be more effectively converted into a plurality of organic acids and short-chain fatty acids with more excellent preservative and antibacterial effects, and the preservative and antibacterial effects of the post-biogen composition are improved.

The invention relates to the technical field of intelligent food production, in particular to a probiotic plant beverage production method and system.The method comprises the steps that mildewed and damaged areas of penthorum chinense pursh, gastrodia elata and other plant raw materials are recognized and removed, the content of reducing sugar is detected, and a traceability identifier is generated; the preparation method comprises the following steps: compounding lactobacillus plantarum A, lactobacillus plantarum B and lactobacillus paracasei, embedding by adopting a sporopollen-calcium alginate core-shell structure, and adjusting the thickness of a shell layer and the concentration of carboxymethyl pachymaran; correcting Arrhenius equation activation energy Ea through bacterial colony density data so as to calculate the attenuation rate k value in the shelf life; after the fermentation liquor is embedded for the second time, QR code labels are generated for products qualified in primary inspection, and RFID temperature and humidity sensing chips are integrated; and pushing real-time shelf lives of qualified finished products, probiotic flora activity reports and traceability identifiers to consumers. According to the invention, the problems of low efficiency, lag in fermentation regulation, backward traceability technology and isolated intelligent technology of the traditional process are solved.

The invention discloses an application of Lactobacillus brevis 146 (Lactobacillus brevis 146) in improving the bioavailability of GABA (gamma-aminobutyric acid) (gamma-aminobutyric acid). According to the present invention, the specific Lactobacillus brevis 146 is adopted, such that the component of GABA is enriched, the GABA is more diversified, and the GABA, the dead bacteria component of the postbiotics, and the other metabolic components such as the active components such as polysaccharide are provided, such that the bioavailability of the GABA is improved; therefore, the lactobacillus brevis 146 and the GABA can be combined for use, and the lactobacillus brevis 146 can be used for preparing the medicine for treating the nervous system and intestinal diseases, and can be used for preparing food and health care products.

This invention relates to the technical field of deep processing of sturgeon by-products, and particularly to a sturgeon tendon peptide with antioxidant and pancreatic lipase inhibitory activities and its preparation method. The preparation method includes the following steps: mixing sturgeon with water and crushing it to form a first slurry; adding Bacillus licheniformis alkaline protease to the first slurry for a first hydrolysis; adding Bacillus subtilis neutral protease to the first hydrolysate for a second hydrolysis; adding a complex enzyme to the second hydrolysate for a third hydrolysis to obtain a sturgeon tendon hydrolysate; filtering the sturgeon tendon hydrolysate to remove impurities to obtain a filtrate, which is then filtered again to retain polypeptides, thus obtaining the sturgeon tendon peptide; wherein the complex enzyme includes pectinase and amylase. Using this method, a sturgeon tendon peptide with high glycosaminoglycan content can be obtained, which exhibits pancreatic lipase inhibitory activity, antioxidant activity, Staphylococcus aureus inhibitory activity, and prebiotic effects that promote the proliferation of Lactobacillus plantarum and Lactobacillus fermentum.

The invention discloses lactobacillus mucus HG002 and application thereof, and belongs to the field of microbial medicine. The lactobacillus mucilaginosus HG002 is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC NO.36670, and the 16S rDNA gene sequence of the lactobacillus mucilaginosus HG002 is as shown in SEQ ID NO: 1. The strain is separated from excrement of healthy adults, the relieving effect of ALF is remarkably improved through the brand-new fermentation lactobacillus mucus HG002 strain and derivative EVs thereof in combination with a synergistic effect mechanism and optimized product design, many defects in the prior art are overcome, and wide application prospects and industrialization value are achieved.

The invention discloses a lactobacillus reuteri strain and an application of the lactobacillus reuteri strain in poultry breeding. The strain name of the lactobacillus reuteri strain is Lac-R30, and the lactobacillus reuteri strain is preserved in the Guangdong Microbial Culture Collection Center, and the preservation number is GDMCC NO. 66690. According to the invention, the lactobacillus with high adhesiveness is separated and screened from the intestinal tract of chicken, which is crucial for ensuring the effective colonization and probiotic function exertion of the lactobacillus in the intestinal tract of poultry. The adhesiveness and field planting efficiency of the lactobacillus reuteri strain Lac-R30 in intestinal tracts are not reported, and the breakthrough of strain resources is realized. The lactobacillus reuteri strain Lac-R30 disclosed by the invention has remarkable advantages in adhesiveness and field planting efficiency due to high adaptability of the lactobacillus reuteri strain Lac-R30 to poultry hosts. The lactobacillus reuteri strain Lac-R30 disclosed by the invention not only provides a high-quality strain resource for researching and developing a poultry probiotic preparation which is more efficient and more targeted, but also lays a solid foundation for improving the application effect of probiotics in actual breeding.

The invention provides application of a lactobacillus mucus fermentation strain A21196 in preparation of a product for promoting ethanol metabolism, and belongs to the technical field of microbial preparations. The lactobacillus mucus fermentation strain A21196 has the high-yield ethanol dehydrogenase and acetaldehyde dehydrogenase, and has the effects of reducing the content of ethanol and acetaldehyde in the blood of mice suffering from acute alcoholism and shortening the central nervous inhibition time in vivo. Therefore, the invention provides the application of the fermented lactobacillus mucus strain A21196 in preparation of a product for preventing and / or treating the alcoholic liver injury or the alcoholic liver disease.

The invention belongs to the technical field of probiotics, and particularly relates to fermented lactobacillus mucus BM01 with an effect of relaxing bowel and application of the fermented lactobacillus mucus BM01. A new fermented lactobacillus mucus BM01 strain is separated from excrement of a healthy infant in Guangzhou city, Guangdong province, a zebra fish constipation model is constructed through loperamide hydrochloride, and research finds that the strain can remarkably promote intestinal tract movement, increase the content of in-vivo serotonin and inhibit the enzyme activity of dipeptidyl peptidase-4, so that the constipation of the zebra fish can be inhibited, the constipation of the zebra fish can be inhibited, and the constipation of the zebra fish can be inhibited. Therefore, the bowel relaxing effect is achieved. It is indicated that the BM01 strain can play the bowel relaxing effect through multiple mechanisms, has significant application value, can be used for research and development of drugs for treating constipation, irritable bowel syndrome and other intestinal diseases or development of health care products with the bowel relaxing effect, and can also be used as a feed additive to improve animal intestinal health and reduce disease risks. The culture benefit is improved.

The invention discloses combined lactobacillus salivarius CCFM1327 capable of inhibiting foaming of macrophages and relieving periodontitis, and belongs to the technical field of microorganisms. According to the invention, the strain of combined lactobacillus salivarius CCFM1327 is obtained, and the combined lactobacillus salivarius has the effects of inhibiting foaming of macrophages and relieving periodontitis, which are specifically reflected in that the combined lactobacillus salivarius can inhibit foaming of RAW264.7 cells caused by ox-LDL; the growth of porphyromonas gingivalis can be effectively inhibited; the periodontal probing and diagnosing depth of the periodontitis rats can be obviously reduced; the number of pathogenic bacteria in the oral cavity of the periodontitis rat is reduced; the level of an inflammatory factor IL-17A in serum is reduced; alveolar bone loss of rats suffering from periodontitis is reduced; and the number of alveolar bone osteoclasts is reduced.

The invention relates to the technical field of microorganisms, and discloses a lactobacillus delbrueckii subsp. Bulgaricus XJFY201503 and an application thereof in improving an immune function, the lactobacillus delbrueckii subsp. Bulgaricus XJFY201503 is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC NO.30047, and the preservation time is March 18, 2024. The lactobacillus delbrueckii subsp. Bulgaricus XJFY201503 can be used for directly improving the immune function of an immunosuppressive mouse by protecting and maintaining normal physiological structures of central and peripheral immune organs and promoting secretion of serum cytokines and immune globulins; and the immune function of the mouse can be indirectly promoted by relieving intestinal inflammation reaction.

The invention discloses a porcine epidemic diarrhea virus (PEDV) infection resistant Min pig source lactobacillus salivarius LSM231 and application thereof, and belongs to the technical field of microorganisms. The Min pig source lactobacillus salivarius is named as Ligilbacillus salivarius LSM231 and is preserved in the China Center for Type Culture Collection, the preservation number is CCTCC NO: M 20242330, and the preservation time is October 25, 2024. The Min pig source lactobacillus salivarius has the advantages that the Min pig source lactobacillus salivarius is named as Ligilbacillus salivarius LSM231 and is preserved in the China Center for Type Culture Collection (CCTCC); the screened Min pig source lactobacillus salivarius is symbiotic probiotics in intestinal tracts and is high in safety performance, and experimental results show that the Min pig source lactobacillus salivarius LSM231 has relatively good antibacterial, acid-resistant and cholate-resistant characteristics, has a remarkable PEDV (porcine epidemic diarrhea virus) resisting effect, and can relieve clinical symptoms caused by PEDV infection and promote growth of piglets, so that the Min pig source lactobacillus salivarius LSM231 can be used for preventing and treating the porcine epidemic diarrhea. The compound can replace antibiotics to be used for preparing a micro-ecological preparation for resisting PEDV (porcine epidemic diarrhea virus) infection.

The invention relates to the technical field of microorganisms, in particular to space breeding combined lactobacillus salivarius ZK-88-S and application thereof. The combined lactobacillus salivarius ZK-88-S disclosed by the invention is preserved in the China General Microbiological Culture Collection Center (CGMCC) on December 24, 2024, and the preservation number is CGMCC No.33181; the combined lactobacillus salivarius ZK-88-S can inhibit escherichia coli, staphylococcus aureus, candida albicans, pseudomonas aeruginosa, fusobacterium nucleatum, porphyromonas gingivalis, streptococcus mutans, streptococcus salivarius, streptococcus gordoni or actinomyces naessii, and can be applied to preparation of medicines, daily necessities or health-care foods for oral treatment and oral cleaning.